EGFR Mutant Subset Analysis From Archer 1009: a Randomized Double Blind Phase 3 Efficacy and Safety Study of Dacomitinib Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Titel:
EGFR Mutant Subset Analysis From Archer 1009: a Randomized Double Blind Phase 3 Efficacy and Safety Study of Dacomitinib Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Auteur:
Paz-Ares, L. O'Byrne, K. Mok, T.S.K. Boyer, M. Jänne, P.A. Goldberg, Z. Mather, C. Taylor, I. Zhang, H. Ramalingam, S.S.